LEGNLegend Biotech Corp

Nasdaq legendbiotech.com


$ 42.60 $ 1.81 (4.44 %)    

Friday, 21-Jun-2024 15:59:59 EDT
QQQ $ 479.17 $ 0.00 (0 %)
DIA $ 391.56 $ -0.73 (-0.19 %)
SPY $ 544.47 $ -0.73 (-0.13 %)
TLT $ 93.75 $ 0.00 (0 %)
GLD $ 214.79 $ -3.38 (-1.55 %)
$ 42.61
$ 41.36
$ 0.00 x 0
$ 42.61 x 100
$ 40.80 - $ 42.85
$ 38.60 - $ 77.32
1,104,357
na
15.5B
$ 0.58
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-reiterates-outperform-on-legend-biotech-maintains-86-price-target

RBC Capital analyst Leonid Timashev reiterates Legend Biotech (NASDAQ:LEGN) with a Outperform and maintains $86 price target.

 piper-sandler-reiterates-overweight-on-legend-biotech-maintains-90-price-target

Piper Sandler analyst Edward Tenthoff reiterates Legend Biotech (NASDAQ:LEGN) with a Overweight and maintains $90 price target.

 legend-biotechs-cancer-drug-the-most-attractive-product-set-for-growth-analyst

Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product.

 truist-securities-initiates-coverage-on-legend-biotech-with-buy-rating-announces-price-target-of-88

Truist Securities analyst Asthika Goonewardene initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Buy rating and anno...

 novavax-and-agios-pharmaceuticals-were-among-the-10-biggest-mid-cap-gainers-last-week-june-1-june-7-are-these-in-your-portfolio

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...

 hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-73-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $73 price t...

 hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-73-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $73 price t...

Core News & Articles

73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patien...

 hc-wainwright--co-maintains-buy-on-legend-biotech-lowers-price-target-to-73

HC Wainwright & Co. analyst Mitchell Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price targe...

 deutsche-bank-initiates-coverage-on-legend-biotech-with-buy-rating-announces-price-target-of-60

Deutsche Bank analyst James Shin initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Buy rating and announces Price Ta...

 rbc-capital-maintains-outperform-on-legend-biotech-raises-price-target-to-86

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and raises the price target fro...

 hc-wainwright--co-maintains-buy-on-legend-biotech-lowers-price-target-to-86

HC Wainwright & Co. analyst Mitchell Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price targe...

 legend-biotech-q1-2024-gaap-eps-016-beats-034-estimate-sales-93991m-miss-152631m-estimate

Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34...

 hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-87-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

 hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-87-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...